Suchergebnisse - "Pais de Barros, Jean-Paul"

PubPharm (6)

1

Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes

enthalten in: Cardiovascular diabetology | 2023

von Denimal, D. | Bergas, V. | Pais-de-Barros, J. | +9

2

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus

enthalten in: Arteriosclerosis, thrombosis, and vascular biology | 2018

von Vergès, B. | Duvillard, L. | Pais de Barros, J. | +7

3

Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice

enthalten in: Arteriosclerosis, thrombosis, and vascular biology | 2011

von Sberna, A. | Assem, M. | Xiao, R. | +11

4

Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes

enthalten in: Journal of lipid research | 2009

von Vergès, B. | Florentin, E. | Baillot-Rudoni, S. | +6

5

Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes

enthalten in: Journal of lipid research | 2006

von Masson, D. | Pais de Barros, J. | Zak, Z. | +6

6

Effect of cholesteryl ester transfer protein (CETP) expression on diet-induced hyperlipidemias in transgenic rats

enthalten in: Atherosclerosis | 2005

von Zak, Z. | Gautier, T. | Dumont, L. | +9

1
[1]